Elo Mutual Pension Insurance Co Buys 9,352 Shares of Bristol Myers Squibb Company $BMY

Elo Mutual Pension Insurance Co boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 4.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 244,412 shares of the biopharmaceutical company’s stock after acquiring an additional 9,352 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Bristol Myers Squibb were worth $11,314,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Brighton Jones LLC grew its holdings in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Mackenzie Financial Corp increased its holdings in shares of Bristol Myers Squibb by 53.7% during the first quarter. Mackenzie Financial Corp now owns 900,576 shares of the biopharmaceutical company’s stock valued at $54,926,000 after acquiring an additional 314,810 shares in the last quarter. Norden Group LLC lifted its stake in shares of Bristol Myers Squibb by 0.8% in the first quarter. Norden Group LLC now owns 92,820 shares of the biopharmaceutical company’s stock valued at $5,661,000 after buying an additional 744 shares in the last quarter. Baldwin Investment Management LLC increased its holdings in Bristol Myers Squibb by 50.4% during the 1st quarter. Baldwin Investment Management LLC now owns 14,132 shares of the biopharmaceutical company’s stock worth $862,000 after purchasing an additional 4,733 shares in the last quarter. Finally, Maridea Wealth Management LLC purchased a new position in Bristol Myers Squibb during the 1st quarter worth $204,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BMY has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Citigroup cut their price target on shares of Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating on the stock in a report on Monday, November 17th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Finally, Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Four research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $54.42.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Trading Up 3.4%

BMY opened at $47.83 on Tuesday. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The stock has a market cap of $97.37 billion, a PE ratio of 19.29, a PEG ratio of 2.23 and a beta of 0.33. The business has a 50 day moving average of $45.31 and a 200-day moving average of $46.57. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter last year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.2%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.